Where does Debregeas ET Associes Pharma rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Debregeas ET Associes Pharma ranks #46,069 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Debregeas ET Associes Pharma hold?

Debregeas ET Associes Pharma holds 5 US utility patents granted between 2015 and 2023, spanning 2 technology areas.

What is Debregeas ET Associes Pharma's Innovation Score?

Debregeas ET Associes Pharma has an Innovation Score of 24.0 out of 100 (13th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Debregeas ET Associes Pharma's patent grant rate increasing or decreasing?

Debregeas ET Associes Pharma's recent grant velocity is -75% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Debregeas ET Associes Pharma's patents?

Debregeas ET Associes Pharma's patents average 10.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Debregeas ET Associes Pharma patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Debregeas ET Associes Pharma

Q: What technology areas does Debregeas ET Associes Pharma focus on?

Debregeas ET Associes Pharma's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents. Grants appear in 2 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 2 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Debregeas ranks #46,069 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 2 technology areas.

#46,069
of 49,997 US assignees by volume: 13th percentile
by Innovation Score (24.0/100): 10.2
avg claims per patent: -75%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R46069 · Foreign Corporation #46,069 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #46,069/49,997
PHOTO-FINISH DE Nora Holdings US
CPC-NARROW A61P · 2 areas
INNOV-THIN 24.0/100
CLAIMS-PAR 10.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -75% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: DE Nora Holdings US, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Debregeas ET… · this assignee

24
3D Lighting… · lowest

7

What this shows Debregeas's Innovation Score is 24.0/100 (13th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Debregeas's grants concentrate

Debregeas ET Associes Pharma is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). By volume, Debregeas sits between DE Nora Holdings US, Inc. and Deepqure Inc..

Debregeas's three-year grant acceleration

Debregeas ET Associes Pharma shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

DE Nora Holdings…

5
Dealerware

5
Dean Technology

5
Deborah A Lambert…

5
Decon7 Systems

5
Deep Instinct

5
Deepinfar Ocean T…

5
Deepqure

5
Debregeas ET Asso… ◀

5

What this shows Debregeas holds 5 patents at rank #46,048, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Debregeas

By rank, the assignees closest to #46,048 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Debregeas's primary technology class.

Debregeas's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

24 13th percentile higher than 13% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Debregeas ET Associes Pharma patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	20.0%
2017	1	20.0%
2018	1	20.0%
2019	1	20.0%
2023	1	20.0%

Which technologies does Debregeas ET Associes Pharma patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

Top 2 of 2 technology areas

Where it ranks

Overall rank by patents

#46,069

of 49,997 tracked assignees

Innovation Score

24.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Debregeas ET Associes Pharma's patent record in context - here's where to go next.

Debregeas ET Associes Pharma's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #46,069 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Debregeas ET Associes Pharma against DE Nora Holdings US, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 24.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.